SBIR-STTR Award

Rat and Canine Microphysiological Systems of the Kidney Proximal Tubule for Chemical Toxicity Screening
Award last edited on: 5/9/2022

Sponsored Program
SBIR
Awarding Agency
NIH : NIEHS
Total Award Amount
$1,931,768
Award Phase
2
Solicitation Topic Code
113
Principal Investigator
Thomas Neumann

Company Information

Nortis Inc

17280 Woodinville Redmond Road NE Suite B-828
Woodinville, WA 98072
   (206) 414-5631
   info@nortisbio.com
   www.nortisbio.com
Location: Single
Congr. District: 01
County: King

Phase I

Contract Number: 1R44ES032393-01
Start Date: 8/20/2020    Completed: 4/30/2021
Phase I year
2020
Phase I Amount
$252,114
Humans are constantly exposed to a variety of chemicals via food, household products, medicines, and the environment. The kidney is particularly susceptible to chemical damage; drug-induced nephrotoxicity is a major health concern that contributes to 25% of all cases of severe acute kidney failure. Nephrotoxicity is also a significant problem in drug development; it is a major cause of attrition late in the process, accounting for 19% of failed Phase III clinical trials. The limitations of state-of-the-art animal models and in vitro tools for predicting human nephrotoxicity are well acknowledged, which has sparked the development of advanced 3D in vitro models of human tissues and organs, so called organ-on-chip systems (OOC) or microphysiological systems (MPS). While progress with human-based MPS has been rapid, a translational gap remains between MPS data and in vivo data. Therefore, comparing observations from animal-based MPS to in vivo animal data will inform our ability to translate human MPS findings to clinical medicine. This fast-track grant application proposes the development of kidney proximal tubule (KPT) MPS from two animal species that are frequently used in kidney toxicity screening: rat and dog. Once successfully developed, validated, and commercialized, the KPT-MPS will serve as an important new tool in chemical toxicity screening and drug development, allowing cross-referencing animal-based MPS data with in vivo animal data, human- based MPS data and clinical outcomes. It also has the potential to replace some animal testing, significantly reducing the use of live animals in preclinical testing. Phase I of the project is designed to establish robust KPT-MPS models from rat and dog. The project will leverage the commercially available Nortis MPS platform and pre-established protocols for creating human based KPT- MPS. Phase I/AIM 1 will demonstrate that proximal tubule cells from rat and dog form viable and structurally complete proximal tubules and that these tubules exhibit a stress response when exposed to compounds that are toxic to KPTs in vivo (Phase I/AIM 2). Feasibility requirements will be established in at least one of the two species before the project progresses into Phase II. Phase II will focus on optimizing the rat and or dog KPT- MPS prototypes and on developing assays for testing potentially nephrotoxic compounds (Phase II/AIM 1). For these efforts we will leverage a new microfluidic chip made of an injection-molded thermoplastic material that was developed for a human-based KPT-MPS. During Phase II/AIM 2, a panel of five compounds with published species-specific nephrotoxicity for rat, dog, and human will be tested in the KPT-MPS with the goal to establish correlation between KPT-MPS data and in vivo data in all three species. Phase II/AIM 3 is to demonstrate that rat/dog KPT-MPSs can be shipped to future customers as a plug & play pre-seeded product.

Public Health Relevance Statement:
Project Narrative The project aims to develop three-dimensional kidney cell culture models from experimental animals rat and dog for screening chemicals to identify potential hazards to human health and the environment. If successful, the proposed technology will enable initial screening efforts that reduce the need for extensive in vivo animal studies. In addition, data resulting from the technology will help understanding data obtained from human based kidney cell culture models and data generated in vivo toxicology experiments.

Project Terms:
3-Dimensional; Accounting; Acute Kidney Failure; Advanced Development; American; animal data; Animal Model; Animal Testing; Animals; Apical; Applications Grants; Back; base; biological adaptation to stress; Biological Assay; Biological Models; Canis familiaris; Cell Culture System; Cell Culture Techniques; Cell Survival; Cells; Chemicals; Clinical; Clinical Medicine; Data; design; Devices; drug development; Environment; Exhibits; experience; Experimental Animal Model; experimental study; Exposure to; Food; Future; Genes; Goals; Harvest; hazard; Health; Hepatocyte; Household Products; Human; human model; human tissue; In Vitro; in vitro Model; in vivo; Inflammation; Injections; Injury; Injury to Kidney; Kidney; kidney cell; Laboratories; Laboratory culture; Lipids; Location; Medicine; Microfluidic Microchips; Microfluidics; microphysiology system; Modeling; Molds; nephrogenesis; nephrotoxicity; Organ; organ on a chip; Outcome; Performance; performance tests; Pharmaceutical Preparations; Phase; Phase III Clinical Trials; Play; Poison; Polymyxin B; Preclinical Testing; predictive tools; Process; Protocols documentation; prototype; Proximal Kidney Tubules; Publishing; rat KIM-1 protein; Rattus; Regulation; response to injury; Running; sample collection; screening; Seeds; Shipping; Ships; Site; Stains; Structure; System; Technology; Testing; Time; tool; Toxic effect; toxicant; Toxicology; Translating; Up-Regulation; Variant

Phase II

Contract Number: 4R44ES032393-02
Start Date: 5/14/2021    Completed: 4/30/2023
Phase II year
2021
(last award dollars: 2022)
Phase II Amount
$1,679,654

Humans are constantly exposed to a variety of chemicals via food, household products, medicines, and theenvironment. The kidney is particularly susceptible to chemical damage; drug-induced nephrotoxicity is a majorhealth concern that contributes to 25% of all cases of severe acute kidney failure. Nephrotoxicity is also asignificant problem in drug development; it is a major cause of attrition late in the process, accounting for 19%of failed Phase III clinical trials. The limitations of state-of-the-art animal models and in vitro tools for predictinghuman nephrotoxicity are well acknowledged, which has sparked the development of advanced 3D in vitromodels of human tissues and organs, so called organ-on-chip systems (OOC) or microphysiological systems(MPS). While progress with human-based MPS has been rapid, a translational gap remains between MPS dataand in vivo data. Therefore, comparing observations from animal-based MPS to in vivo animal data will informour ability to translate human MPS findings to clinical medicine.This fast-track grant application proposes the development of kidney proximal tubule (KPT) MPS from two animalspecies that are frequently used in kidney toxicity screening: rat and dog. Once successfully developed,validated, and commercialized, the KPT-MPS will serve as an important new tool in chemical toxicity screeningand drug development, allowing cross-referencing animal-based MPS data with in vivo animal data, human-based MPS data and clinical outcomes. It also has the potential to replace some animal testing, significantlyreducing the use of live animals in preclinical testing.Phase I of the project is designed to establish robust KPT-MPS models from rat and dog. The project will leveragethe commercially available Nortis MPS platform and pre-established protocols for creating human based KPT-MPS. Phase I/AIM 1 will demonstrate that proximal tubule cells from rat and dog form viable and structurallycomplete proximal tubules and that these tubules exhibit a stress response when exposed to compounds thatare toxic to KPTs in vivo (Phase I/AIM 2). Feasibility requirements will be established in at least one of the twospecies before the project progresses into Phase II. Phase II will focus on optimizing the rat and or dog KPT-MPS prototypes and on developing assays for testing potentially nephrotoxic compounds (Phase II/AIM 1). Forthese efforts we will leverage a new microfluidic chip made of an injection-molded thermoplastic material thatwas developed for a human-based KPT-MPS. During Phase II/AIM 2, a panel of five compounds with publishedspecies-specific nephrotoxicity for rat, dog, and human will be tested in the KPT-MPS with the goal to establishcorrelation between KPT-MPS data and in vivo data in all three species. Phase II/AIM 3 is to demonstrate thatrat/dog KPT-MPSs can be shipped to future customers as a plug & play pre-seeded product.

Public Health Relevance Statement:
Project Narrative The project aims to develop three-dimensional kidney cell culture models from experimental animals rat and dog for screening chemicals to identify potential hazards to human health and the environment. If successful, the proposed technology will enable initial screening efforts that reduce the need for extensive in vivo animal studies. In addition, data resulting from the technology will help understanding data obtained from human based kidney cell culture models and data generated in vivo toxicology experiments.

Project Terms: